Newtyn Management's Funds Hold About 8% Of QuidelOrtho Without Seeking To Influence Control

The investment manager reported voting and disposal authority over 5,342,283 shares held by its funds.

Share
Newtyn Management's Funds Hold About 8% Of QuidelOrtho Without Seeking To Influence Control

Newtyn Management, an investment manager, reported an about 8% stake in QuidelOrtho, which makes diagnostic tests and the instruments used to run them. Monday's SEC passive ownership disclosure put the position at 5,342,283 shares and certified that the reporting persons were not holding the stock to change or influence company control.

The Funds Behind The Stake

The holdings belonged to funds managed by Newtyn Management as of September 30, 2026. The manager reported 7.8% ownership, rounded to about 8%, because its authority over those funds means their shares can be counted as its beneficial ownership.

Newtyn TE Partners, one of the managed funds and a reporting person alongside the manager, held 3,443,720 shares, representing 5% of the class. Newtyn Partners, the other managed fund, held 1,898,563 shares.

Newtyn Management reported sole authority to vote and dispose of the full position. Newtyn TE Partners reported the same authority over its own holdings; neither reporting person listed shared authority.

The reporting persons retained their passive-investment certification. They certified that neither acquiring nor holding the shares had the purpose or effect of changing or influencing QuidelOrtho's control.

A Stake In Diagnostic Testing

QuidelOrtho serves hospitals, laboratories, physician offices, urgent care clinics, pharmacies, blood banks and donor centers. Its products cover clinical chemistry, immunoassay and molecular testing, rapid point-of-care testing, and blood typing and screening for transfusions. Some tests are sold for home use.

The company sells through its own sales team and distributors, reaching customers in more than 140 countries and territories. Its revenue spans Labs, Transfusion Medicine, Point of Care and Molecular Diagnostics, as well as contract manufacturing and collaborations.

Newtyn's ownership calculation used approximately 68,575,427 outstanding common shares as of July 29, 2026. QuidelOrtho supplied that denominator in its quarterly report filed August 7, 2026.

The reported stake combines the managed funds' holdings under Newtyn Management's voting and disposal authority, with the passive-control certification still in place.

Sources

More on QuidelOrtho

All QuidelOrtho (QDEL) coverage →